Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.47 |
| ▸ | DRD2 | P14416 | 9/20 | 0.47 |
| ▸ | DRD3 | P35462 | 9/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2198557 | 0.84 | DRD2 (0.59) | HDAC1DRD2DRD3PKMKCNH2 | |
| SCHEMBL4919307 | 0.84 | DRD2 (0.46) | HDAC1CYP1A1DRD2DRD3KCNH2 | |
| SCHEMBL6220245 | 0.81 | HDAC1 (0.56) | HDAC1CYP1A1DRD2DRD3PKM | |
| SCHEMBL8471981 | 0.81 | HDAC1 (0.56) | HDAC1CYP1A1DRD2DRD3PKM | |
| SCHEMBL14734293 | 0.79 | HDAC1 (0.56) | HDAC1CYP1A1DRD2DRD3PKM | |
| SCHEMBL3714292 | 0.77 | DRD2 (0.61) | HDAC1CYP1A1DRD2DRD3PKM | |
| Trifluoroacetic Acid SCHEMBL2199631 | 0.77 | DRD2 (0.51) | HDAC1DRD2DRD3PKMKCNH2 | |
| SCHEMBL10498393 | 0.75 | CYP1A1 (0.64) | HDAC1CYP1A1DRD2DRD3 | |
| SCHEMBL12427204 | 0.74 | NOX4 (0.49) | HDAC1CYP1A1DRD2DRD3PKM | |
| SCHEMBL8913255 | 0.73 | HDAC1 (0.67) | HDAC1PKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977334-B2 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity modulator, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | TRIESELMANN THOMAS | 2008-09-25 | — | — | US | disclosed |
| EP-1781620-A1 | NOVEL BETA AGONISTS, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2005108373-A1 | NOVEL BETA AGONISTS, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | WO | disclosed |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234278-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | HDAC1 4294/4885CYP1A1 107/4885DRD2 704/4885 |
| US-20050245526-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | HDAC1 4294/4885CYP1A1 107/4885DRD2 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.